Table 1

Clinical data for patients with CLL with known 17p status*

Characteristic17pDEL (N = 64)NORM/NORM (N = 40)P, χ2 test
No. of male/female 46/18 26/14 .131 
Median age at diagnosis, y (range) 63 (37-89) 61 (37-76) .095 
Median time from diagnosis to sample collection, mo 75.10 81.29  
ZAP-70 expression   .215 
    20% or less 21 17  
    More than 20% 43 23  
IgVH status*   .035 
    Unmutated (≥ 98% homology) 36 18  
    Mutated (< 98% homology) 10 14  
B2M expression*   .002 
    No more than 4 mg/L 27 29  
    More than 4 mg/L 26  
Therapy began after collection    
    No 16 18 .587 
    Yes 14 16  
If therapy received, median time since collection, mo 1.37 0.68  
Treatment-refractory disease 18 < .001 
Characteristic17pDEL (N = 64)NORM/NORM (N = 40)P, χ2 test
No. of male/female 46/18 26/14 .131 
Median age at diagnosis, y (range) 63 (37-89) 61 (37-76) .095 
Median time from diagnosis to sample collection, mo 75.10 81.29  
ZAP-70 expression   .215 
    20% or less 21 17  
    More than 20% 43 23  
IgVH status*   .035 
    Unmutated (≥ 98% homology) 36 18  
    Mutated (< 98% homology) 10 14  
B2M expression*   .002 
    No more than 4 mg/L 27 29  
    More than 4 mg/L 26  
Therapy began after collection    
    No 16 18 .587 
    Yes 14 16  
If therapy received, median time since collection, mo 1.37 0.68  
Treatment-refractory disease 18 < .001 

ZAP-70 indicates 70-kDa ζ-associated protein; IgVH, immunoglobulin heavy-chain variable-region gene; and B2M, β-2 microglobulin.

*

Status of IgVH and B2M was known for 78 and 88 patients, respectively.

or Create an Account

Close Modal
Close Modal